Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 37-42

  Cao, Yunfei ^a   Liu, Lidan ^a   Liao, Cun ^a   Tan, Aihua ^a   Gao, Feng ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Cetuximab; Hypokalemia

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE CLASSIFICATION; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STOMACH CANCER; SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; HYPOKALEMIA; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT;

EID: 77951885057     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1131-5     Document Type: Article

References (28)

1. Baselga J (2001) The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37(Suppl 4):S16-S22
2. Kim ES, Khuri FR, Herbst RS (2001) Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13(6):506-513
3. Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (Suppl 1):15-23 (discussion 41-42)
4. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 11:755-768
5. Ciardiello F (2000) Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 (Suppl 1):25-32 (discussion 41-42)
6. Liu L, Cao Y, Tan A, Liao C, Gao F (2009) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a metaanalysis of 17 randomized controlled trials. Cancer Chemother Pharmacol [Epub ahead of print]
7. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
9. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(864):6-8654
10. Lin SH, Halperin ML (2007) Hypokalemia: a practical approach to diagnosis and its genetic basis. Curr Med Chem 14:1551-1565
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12
12. US National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep. cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
13. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24(7):1072-1078
14. Cartwright TH, Kuefler P, Cohn A, Hyman W, Boehm KA, Ilegbodu D, Asmar L (2006) Results of a phase II trial of cetuximab + XELIRI as Wrst-line therapy of patients with advanced and/or metastatic colorectal cancer. J Clin Oncol 24(18S):13502
15. Bennouna J, Faroux R, François E, Ligeza C, El Hannani C, Perrier H, Jacob J, Desseigne F, Perrocheau G, Douillard JY (2007) CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC) : preliminary results from a multicenter phase II trial. J Clin Oncol 25(18S):4087
16. Birnbaum AE, Johnson TT, Rathore R, Khurshid H, Puthawala M, Radie Keane K, Ruhl C, Wanebo H, Kennedy T, Ready N, Br UOG (2007) Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RT) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). In: Annual meeting proceedings part I. (20 June Supplement). J Clin Oncol 25(18S):16504
17. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 113:2512-2517
18. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA (2008) A phase II study of cetuximab/paclitaxel/ carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 110:140-145
19. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Rojas Llimpe FL, Cascinu S, Giaquinta S, Schinzari G, Mutri V, Martoni AA, Br U.O.G. (2008) Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study). In: ASCO annual meeting proceedings part I. (20 June Supplement). J Clin Oncol 25(18S):16504
20. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395
21. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA III (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319
22. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-11127
23. Kokot F, Hyla-Klekot L (2008) Drug-induced abnormalities of potassium metabolism. Pol Arch Med Wewn 118:431-434
24. Ben Salem C, Hmouda H, Bouraoui K (2009) Drug-induced hypokalaemia. Curr Drug Saf 4:55-61
25. Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T (2004) Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci USA 101(9):2894-2899
26. Groenestege WM, Thebault S, Van Der Wijst J et al (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117:2260-2267
27. Whang R, Welt LA (1963) Observations in experimental magnesium depletion. J Clin Invest 42:305-313
28. Hoskote SS, Joshi SR, Ghosh AK (2008) Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India 56:685-693